A proprietary drug-device combination containing 0.7% cantharidin – a substance secreted by blister beetles to defend themselves – is safe and effective for children with molluscum contagiosum, according to two trials.

Although the highly contagious condition is self-limiting in immunocompetent individuals, the average duration is often measured in years, the authors said.

In the Phase 3 CAMP trials (Cantharidin Application in Molluscum Patients) spanning 31 centres across the US, some 527 participants (mean age seven years, 50% boys) were randomised (3:2) to apply the therapy, known as VP-102, or vehicle topically.

Application was to all treatable lesions every 21 days until complete lesion clearance or up to four treatments.